Exoduspoint Capital Management Reduces $10M in ABIVAX Société Anonyme ($ABVX)
Key Points
- Exoduspoint Capital Management changed its ABIVAX Société Anonyme ($ABVX) stake by 34.84% last quarter, cutting to 140,262 shares worth $18.63 million.
- $ABVX last traded around $132.83.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Exoduspoint Capital Management reduced its position in ABIVAX Société Anonyme ($ABVX) by 34.84% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 140,262 shares of ABIVAX Société Anonyme after selling 75,011 shares during the quarter. Exoduspoint Capital Management's holdings in ABIVAX Société Anonyme were worth $18.63 million as of its most recent filing.
ABIVAX Société Anonyme Stock Up 17.2%
Shares of ABIVAX Société Anonyme ($ABVX) traded around $132.83 on Saturday, up 17.2% for the day.
ABIVAX Société Anonyme Earnings
Analysts Set New Price Targets
About ABIVAX Société Anonyme
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Get ABIVAX Société Anonyme alerts
New 13F filings, insider trades, and analyst moves on $ABVX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.